Salbutamol

High performance APIs for inhalation as well as other demanding applications.  The diversity and experience in particle size reduction technologies provides our Customers with tailored made, highly reproducible particle size distributions. Low amorphous content and high stability w...

Proven expertise in development of high performance APIs for demanding applications such as inhalation or nasal suspensions. The range of particle size reduction technologies enables the manufacture of tailor made material with high particle size distribution reproducibility across batches a...

LABA/LAMAROUTE OF ADMINISTRATION: Inhalation
REGULATORY STATUS: DEV

ROUTE OF ADMINISTRATION: Oral, Injectable

REGULATORY STATUS: DEV

ROUTE OF ADMINISTRATION: Injectable

REGULATORY STATUS: DEV, TECH PACK

A very high purity grade product available from a reliable European source

ROUTE OF ADMINISTRATION: Oral

REGULATORY STATUS: CEP, JP DMF

Hovione has a proven track record in developing and manufacturing high performance APIs for the most demanding applications such as inhalation. With an unrivalled range of particle size reduction technologies for the production of tailor made API, featuring a near-perfect particle size distribution re...

ROUTE OF ADMINISTRATION: Oral, Topical  

REGULATORY STATUS: DEV

ROUTE OF ADMINISTRATION: Oral

REGULATORY STATUS: DEV

ROUTE OF ADMINISTRATION: Injectable

REGULATORY STATUS: DEV, TECH PACK

 Tiotropium Bromide for development trials with customized Particle Design, manufactured by wet polishing, resulting in Inhalation grade material with highly customizable PSD to befit your application.
Our technology and expertise range yields unmatched impurity profiles with highly reproducib...

Umeclidinium Bromide for formulation development trials with customized Particle Engineering, resulting in Inhalation grade material with highly customizable PSD to enhance your formulation’s performance. Our technology and expertise yields unmatched impurity profiles with highly reproducibility betwe...

The new 31,000-sq. ft building will bring additional commercial spray drying capacity for customers who favour US-based manufacturing

Hovione announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Operating Officer (COO), effective May 1st, 2020.

Hovione announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®

Ventofor Combi Fix delivered by the PowdAir Plus dry powder inhaler.